Etanercept Biosimilar (Mabxience Holdings)

依那西普生物类似药（Mabxience Holdings）

Report date: 2024/09/20 20:00:41

Base Information

Drug NameEtanercept Biosimilar (Mabxience Holdings)
Drug Alias NameMB04MB-04
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor α inhibitorsTumor necrosis factor β inhibitors
TargetsTumor necrosis factor αTumor necrosis factor β
Therapy Area/IndicationsAutoimmune DiseasesArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaPolandRomania +[7] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesMabxience Holdings SL
China Registration ClassN/A

Develop Information

Active CompaniesMabxience Holdings SLMabxience Research SL
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeL04AB01
Related LinksN/A